Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

PV0315_TarenGromPatient-centric, patient-centricity, patients at the center…these buzzwords or terms are permeating the healthcare industry consciousness. Like Tom Hanks’ character in You’ve Got Mail, I too, believe most of life’s questions can be answered by the Godfather, so to paraphrase the Michael Corleone: It’s not personal, it’s business. But the business of medicine is highly personal, and always has been. True, pharmaceutical companies have stockholders to report to, but this doesn’t mean they haven’t had patients squarely in their focus the whole time.

Take for example one of the industry’s largest pharmaceutical companies — Johnson & Johnson. Nobody can say Chairman of the Board and CEO Alex Gorsky doesn’t have a keen eye on the bottom line, but he also is incredibly dedicated to making sure the company lives up to its credo, the first line of which defines the company’s actions in all it does: “We believe our first responsiblity is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services.”

This month’s cover story — The Patient Journey: Moments of Care — examines the highly matrixed environment of patient centricity. There is consensus among the experts who contributed to this article who say a successful patient-centric plan requires two elements: knowing the patient and collaboration across all stakeholders.

The industry’s apparent renewed focus on the patient is being fueled by the new healthcare economy and to the delivery of customer-centered care. PwC defines the new health economy as one in which “patients” will be “consumers” first, with both the freedom and responsibility that come with making more decisions and spending their own money. These consumers will demand a continuum of well-being, rewarding the trusted advisers that can help achieve that.

PwC says in the new health economy, the mere collection of data will be replaced with lightning-fast analysis delivered directly to a care team that anticipates problems before they arise. Individuals will be co-creators of their health decisions, spending more of their discretionary dollars on tools that help them live well.

How these patients are reached in a mobile-everything, Internet of Things, digital age is being sorted out on a daily basis and by myriad stakeholders — traditional and nontraditional — looking for a piece of a very valuable pie. In reality, the revenue opportunity in the new health economy, says PwC, is much greater than $2.8 trillion fragmented system of healthcare today. In one survey by PwC’s Health Research Institute (HRI), consumers indicated they are willing to spend collectively up to $13.6 billion a year of their own money on medical products such as health-related video games and ratings services.

Exciting times lie ahead as this “new” patient-focused trend continues to unfold leading to even better patient care.

Taren Grom

Their word…

Denise MyshkoPV0915_TheirWordLetter
Managing Editor

Gene therapy is once again a growing area of research attracting large and small
companies working to
bring therapies for rare and genetic diseases.

Robin Robinson
Senior Editor

Mobile marketing has evolved into being one of the many significant pieces of an omnichannel campaign.

Kim Ribbink
Features Editor

Pharma R&D investment in Italy is high, demonstrating the sector’s importance within the country’s economy.

Coming in October 2015

Clinical Crowdsourcing
Visual Content
Research of Controlled Substances
Aging Well
Oncology: Marketing
C-Suite: Specialty Pharma
Market Focus: Nigeria
Showcase Features: Supply Chain & Logistic Management and Patient Solutions


The forum for the industry executive

Volume 15 • Number 8
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

design associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Kathy Deiuliis

Copyright 2015
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Fifteen, Number Eight

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.